Publications

Osgood NRB, Zawalick NM, Sawyer CB, Cowan QT, Gu S, Mawson SJ, Ranzau BL, L L, Gymrek M, Goren A, Komor AC. Genome editing with programmable base editors in human cells. Methods in Enzymology. (Academic Press, 2025). doi:10.1016/bs.mie.2025.01.001.

 

Vasquez CA, Osgood NRB, Zepeda MU, Sandel DK, Cowan QT, Peiris MN, Donoghue DJ, Komor AC. Precision genome editing and in-cell measurements of oxidative DNA damage repair enable functional and mechanistic characterization of cancer-associated MUTYH variants. Nucleic Acids Research. 2025 Mar 20;53(6):gkaf037. doi: 10.1093/nar/gkaf037. PMID: 40156857; PMCID: PMC11952967.

 

Powers A, Cheung K, Osgood N, Kudwa A, Shepard P, Datta S, Safadi M, Sinha S, Kerr J, Zhang C, Levin N, Chilcoat D, Jeffries S, Kim J, Siffert J. (2023, April 23-27). Pharmacological and molecular features of DT-168, a topical GeneTACTM small molecule being developed as potential treatment for Fuchs Endothelial Corneal Dystrophy caused by CTG repeat expansions in the TCF4 gene [Poster abstract]. ARVO 2023, New Orleans, LA, United States. https://iovs.arvojournals.org/article.aspx?articleid=2786494

 

Powers A, Rinkoski T, Cheung K, Schehr H, Osgood N, Livelo C, Levin N, Safadi M, Kerr J, Zhang C, Chilcoat ND, Bhat A, Baratz K, Wieben E, & Fautsch M. (2022, May 1-4). GeneTACTM small molecules reduce toxic nuclear foci and restore normal splicing in corneal endothelial cells derived from patients with Fuchs endothelial corneal dystrophy (FECD) harboring repeat expansions in transcription factor 4 (TCF4) [Poster abstract]. ARVO 2022, Denver, CO, United States. https://iovs.arvojournals.org/article.aspx?articleid=2780764